
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics is a promising biopharmaceutical company with a strong portfolio of precision medicines that target biologically validated drivers of cancers. Their lead program OKI-219 is showing promising preclinical results with further potential in solid tumors and vascular anomalies, with expected INDs in 1H27. Additionally, OnKure's unique approach of selectively targeting mutant PI3Kα with minimal effect on wild-type PI3Kα could lead to a more benign adverse event profile and potentially superior efficacy compared to competitors. With a healthy cash reserve and ongoing expansion efforts, OnKure is poised for long-term success and we reiterate our positive outlook on the stock.
Bears say
OnKure Therapeutics is a company with a promising drug development platform, but its current pipeline and business model present significant risks. The company's reliance on one segment for its clinical research and its limited revenue sources make it vulnerable to potential setbacks and market fluctuations. Additionally, the stock's current valuation seems inflated, as the company's NPV of $13.87 only rounds to $14, significantly lower than its current market price.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares